Drugs / CORVax
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04627675 | Dec 2020 → Sep 2022 | COVID-19 | Providence Health & Services | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03823131 | May 2019 → Jul 2022 | head and neck squamous cell carcinoma | Chase Heaton, MD | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CORVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627675 ↗ |
| Modality | Vaccine | “SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine” NCT04627675 ↗ |